Welcome to our dedicated page for Briacell Therapeutics SEC filings (Ticker: BCTXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BriaCell Therapeutics Corp. (BCTXW) SEC filings page on Stock Titan is intended to organize U.S. regulatory documents associated with this Nasdaq-listed security. While no specific SEC filings are listed in the available data, BriaCell is described as a clinical-stage biotechnology company with securities trading on Nasdaq under the symbols BCTX, BCTXW and BCTXZ, and on the Toronto Stock Exchange under BCT. For such issuers, SEC filings typically include registration statements, periodic reports, and disclosures related to financing transactions and capital structure.
For a company like BriaCell, investors often look to annual and quarterly reports (such as Forms 10-K and 10-Q when available) for information on clinical development programs, risk factors, research and development activities, and liquidity. They may also review current reports on Form 8-K for material updates on clinical trial milestones, regulatory designations, collaborations, or financing events, and prospectus supplements related to offerings of common shares, warrants, or other securities linked to symbols such as BCTXW.
On Stock Titan, the BCTXW filings page is designed to surface real-time updates from EDGAR as they become available and pair them with AI-powered summaries that explain the key points of each document in accessible language. This can help readers understand how filings relate to BriaCell’s cancer immunotherapy programs, including Bria-IMT, Bria-OTS, Bria-OTS+ and small-molecule initiatives via BriaPro, without having to parse every technical detail themselves.
Users can also use this page to monitor changes in the company’s capital structure associated with its listed securities, including warrants like BCTXW, and to track how regulatory disclosures align with the clinical and corporate updates highlighted in BriaCell’s news and scientific communications.
BriaCell Therapeutics Corp. is furnishing unaudited interim results for its subsidiary BriaPro Therapeutics and outlining a new oncology licensing deal. For the six months ended January 31, 2026, BriaPro recorded a net loss of $472,231, driven mainly by research and development spending of $433,307. The company has negative working capital of $1,638,799 and a cumulative deficit of $1,652,656, and the statements highlight material uncertainty about its ability to continue as a going concern, with operations funded by BriaCell.
On February 18, 2026, BriaPro agreed to acquire an exclusive worldwide license to develop and commercialize Soluble CD80 (sCD80) for cancer from BriaCell, along with related assets. As consideration and in connection with a $3,000,000 BriaCell credit facility, BriaPro will issue 23,972,589 common shares valued at approximately C$1.18 million, increasing BriaCell’s stake to about 78%. BriaPro will owe a 2% royalty on sCD80 sales to the University of Maryland, Baltimore County. Disinterested shareholders approved the transaction on March 5, 2026, and it closed on March 30, 2026.
BriaCell Therapeutics Corp. filed a Form 25 notifying removal of its Warrant class from listing and registration on the Nasdaq Stock Market LLC.
Nasdaq certified compliance with 17 CFR 240.12d2-2 procedures to strike the class and the filing states the issuer complied with the Exchange's voluntary withdrawal requirements. The notice is signed by Tara Petta, Director.
BriaCell Therapeutics Corp. has called its 2026 annual general and special meeting for March 5, 2026 in Toronto. Shareholders of record on January 26, 2026, representing 7,250,487 common shares, can vote in person or by proxy.
Investors will vote on appointing MNP LLP as auditor, electing six directors, and re-approving BriaCell’s rolling omnibus equity incentive plan, which allows equity awards up to 15% of shares outstanding, with additional caps for insiders and non-employee directors. The Board unanimously recommends voting “FOR” all three proposals.